Overview
Status
Active
Registry date
2010-12-17
Share capital
5,000.00 PLN
Registered address
Puławska 314, 02-819 Warszawa, Poland
Electronic delivery address
AE:PL-71672-48637-TUUWC-21
Financials
Revenue history (in m)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 75 days late). All were audited by a statutory auditor.
- 202530/06/2026
- 202407/07/2025
- 202308/07/2024
- 202206/07/2023
- 202128/09/2022
- 202005/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 24.32mMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 1.14mMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 22.80mMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 7.97mMedianUSD 608.93kAverageUSD 11.85m
Industry
Authorized Representatives
Enguerrand Dubois – Management Board Member
Manner of representation
Each member of the management board may represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2010-12-10.
45 1600 1127 0003 0121 2547 0001
87 1600 1127 0003 0121 2547 0021
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 837PLN 837 |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Centrala Farmaceutyczna CefarmS.A. | $457,052,669.59 | cefarm.com.pl | ||
| ITPS.A. | $55,285,362.18 | itpsa.pl | ||
| Synkmedsp. z o.o. | $20,634,200.47 | synkmed.pl | ||
| Intimexsp. z o.o. + limited partnership | $18,994,512.90 | intimex.com.pl | ||
| IMC Impomed CentrumS.A. | $4,447,564.10 | impomed.pl | ||
| Gtm-Mobil M-T T.Walisiewiczsp. k. | $3,438,533.82 | gtmmobil.com.pl | ||
| Reynolds Medicalsp. z o.o. | $3,313,657.78 | reymed.pl | ||
| Petronafsp. z o.o. | $2,499,010.09 | petronaf.com | ||
| CryoprofilS.A. | $1,470,469.25 | cryoprofil.pl | ||
| Novisc Pharmasp. z o.o. | $806,018.56 | novisc.com |
Change history
| Date | Event | |
|---|---|---|
| 2017-09-05 | PKD change (Removed: 1 code; Added: 6 codes) | |
| 2011-05-25 | Address change (Piękna 18, 00-549, Warszawa → Puławska 314, 02-819, Warszawa) | |
| 2010-12-17 | Entered in the register |
FAQ
The main business activity of Virbac focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on December 17, 2010.
The headquarters is located at: Puławska 314, 02-819 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $22,091,598 in 2024, which is an increase of 14.6% compared to 2023.
Yes, in 2024 the company was profitable, achieving a net profit of $1,182,483, meaning the company increased its profit by 53.9%.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to $16,177,501 in 2024, representing 79% of all operating expenses.
Last updated: 2026-06-30